

the Fungitell® Bulletin

volume 7, issue 4


Topic:

(1→3)-β-GLUCAN: AN INNATE IMMUNE SYSTEM BIOLOGICAL RESPONSE MODIFIER

Discussion:

The introduction of Fungitell®, for serum (1→3)-β-glucan (BG) measurement, greatly expanded the diagnostic armamentarium for invasive fungal disease (IFD) diagnosis through the ability to detect and quantitate minute levels of blood-borne BG¹. While validated as a biomarker of IFD² BG has also been shown to have a significant role in innate immunity, suggesting a concomitant role in immunopathology associated with IFD and other forms of BG exposure^{3,21}. Over the past four decades, (1→3)-β-glucan has been shown to be a potent activator of the innate immune system and to play a role as a biological response modifier in many immune function circuits^{4,5}. These various activities have been elucidated in greater detail through studies of BG-influenced cellular responses, BG receptor knock-outs, and, more recently, the direct measurement of minute levels of BG in biological fluids of animal models and patients and their correlation with immunopathology and outcome⁶. The experimental designs that have enabled this work have included, in pre-clinical models, the administration of BG by intravenous routes⁷ by cecal ligation and puncture^{8,9} by gavage or ingestion¹⁰ and inflammatory injury to the intestinal epithelium¹¹. Measured effects have included changes in cytokine and chemokine elicitation, immune pathway cell differentiation, eicosanoid metabolism, epigenetic modification of chromatin, and others^{12,22}.

Early on, Cook *et. al.*, demonstrated that intravenous (iv) administration of BG to rats, followed, at an interval of three days, by the iv administration of sub-lethal levels of endotoxin resulted in complete lethality⁷. This “BG-priming” effect was shown to potently exacerbate a reticuloendothelial system (RES) response culminating in shock-like symptoms and major physiological perturbation. Panpetch *et. al.*, described similar results, in mice, using gut origin BG and intestinal translocation elicited by dextran sulfate solution (DSS) administration causing



Bulletin Volume 7, issue 4
Publish Date: December 2018

Corporate Headquarters
Associates of Cape Cod, Inc.
124 Bernard E. Saint Jean Drive
East Falmouth, MA 02536 USA
Tel: (508) 540-3444
www.acciusa.com

United Kingdom
Associates of Cape Cod Int'l., Inc.
Deacon Park, Moorgate Road
Knowsley, Liverpool L33 7RX
United Kingdom
Tel: (44) 151-547-7444
www.acciuk.co.uk

European Office
Associates of Cape Cod Europe GmbH
Opelstrasse 14
D-64546 Mörfelden-Walldorf, Germany
Tel: (49) 61 05-96 10 0
www.acciusa.de

(1→3)-β-GLUCAN: AN INNATE IMMUNE SYSTEM BIOLOGICAL RESPONSE MODIFIER

intestinal inflammation¹³. Additional translocated BG effects were observed by Leelahavanichkul *et al.*, who utilized a murine sepsis model to demonstrate large increases in mortality with the oral administration of dead *Candida albicans* cells¹⁴.

The role of BG and Toll-Like Receptor (TLR) ligand cytokine/chemokine elicitation synergy was demonstrated in a human whole blood model by Kikkert *et al.*¹⁵, who observed multifold increases in interleukins-6 and -8. Similar findings were made by Dennehy *et al.*, using macrophage culture and Tumor Necrosis Factor- α as a marker¹⁶. Liu *et al.*, observed pleiotropic effects in theraurubicin-treated hemopoietic- and myelopoietic-lineage cells which received lentinan, a fungal BG, as an experimental therapy. These included blood myeloperoxidase activity increase, increase in the numbers of leukocytes and neutrophils, increases in G-CSF and M-CSF, and an improvement in bone marrow injury¹². Similar BG effects observations were made by Cramer *et al.*^{17,18}.

The role of BG stimulation of cellular cytotoxicity against iC3b-opsonized targets and its potential as an adjunctive antitumor therapy was investigated by Gordon Ross and colleagues, who demonstrated that the ligation of BG to the complement receptor 3 lectin site was a trigger for priming neutrophil cytotoxicity, and the killing of iC3b-opsonized target cells¹⁹. These and other observations of BG-enhanced cellular cytotoxicity form the basis of the use of BG as an adjunctive therapy in cancer treatment²⁰.

A role for BG in chronic inflammation-based hepatic disease was recently elucidated by Yang *et al.*, who showed that gut-originating BG triggered inflammatory responses in the liver²¹. Dectin-1 knockout mice did not demonstrate inflammation. In another aspect of innate immune response impact, BG was shown to have a potentiating effect upon endotoxin-elicited

inflammation in that exposure to BG was observed to reverse the epigenetic changes associated with endotoxin tolerance, through epigenetic reprogramming²².

These studies, and many others, demonstrate that, just as has been done with endotoxin burden assessments, comprehensive analysis of both innate and adaptive immune responses can benefit from assessing BG burdens in both experimental models and, potentially, in patients.

Discussion References:

1. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin. Infect. Dis.* 2004;39:199-205.
2. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin. Infect. Dis.* 2008;46:1813-21.
3. Camilli G, Tabouret G, Quintin J. The Complexity of Fungal β -Glucan in Health and Disease: Effects on the Mononuclear Phagocyte System. *Front. Immunol.* 2018;9:673.
4. Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. *J Hematol. Oncol.* 2009;2:25
5. Wang Q, Sheng X, Shi A, Hu H, Yang Y, Liu L, Fei L, Liu H. β -Glucans: Relationships between Modification, Conformation and Functional Activities. *Molecules.* 2017;22. pii: E257
6. Farhour Z, Mehraj V, Chen J, Ramendra R, Lu H, Routy JP. Use of (1→3)- β -D-glucan for diagnosis and management of invasive mycoses in HIV-infected patients. *Mycoses.* 2018;61:718-722.

continued on page 3...

(1→3)-β-GLUCAN: AN INNATE IMMUNE SYSTEM BIOLOGICAL RESPONSE MODIFIER

7. Cook JA, Dougherty WJ, Holt TM. Enhanced sensitivity to endotoxin induced by the RE stimulant, glucan. *Circ Shock*. 1980;7:225-38.
8. Leelahavanichkul A, Worasilchai N, Wannalardsakun S, Jutivorakool K, Somparn P, Issara-Amphorn J, Tachaboon S, Srisawat N, Finkelman M, Chindamporn A. Gastrointestinal Leakage Detected by Serum (1→3)-β-D-Glucan in Mouse Models and a Pilot Study in Patients with Sepsis. *Shock*. 2016;46:506-518.
9. Issara-Amphorn J, Surawut S, Worasilchai N, Thim-Uam A, Finkelman M, Chindamporn A, Palaga T, Hirankarn N, Pisitkun P, Leelahavanichkul A. The Synergy of Endotoxin and (1→3)-β-D-Glucan, from Gut Translocation, Worsens Sepsis Severity in a Lupus Model of Fc Gamma Receptor IIb-Deficient Mice. *J Innate Immun*. 2018;10:189-201.
10. Panpetch W, Somboonna N, Bulan DE, Issara-Amphorn J, Finkelman M, Worasilchai N, Chindamporn A, Palaga T, Tumwasorn S, Leelahavanichkul A. Oral administration of live- or heat-killed *Candida albicans* worsened cecal ligation and puncture sepsis in a murine model possibly due to an increased serum (1→3)-β-D-glucan. *PLoS One*. 2017;12:e0181439.
11. Yoshioka S, Ohno N, Miura T, Adachi Y, Yadomae T. Immunotoxicity of soluble beta-glucans induced by indomethacin treatment. *FEMS Immunol Med Microbiol*. 1998;21:171-9.
12. Liu Q, Dong L, Li H, Yuan J, Peng Y, Dai S. Lentinan mitigates theraurubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-κB-dependent manner. *Oncol Rep*. 2016;36:315-23.
13. Panpetch W, Chanchaoentana W, Bootdee K, Nilgate S, Finkelman M, Tumwasorn S, Leelahavanichkul A. *Lactobacillus rhamnosus* L34 Attenuates Gut Translocation-Induced Bacterial Sepsis in Murine Models of Leaky Gut. *Infect Immun*. 2017;86. pii: e00700-17. doi: 10.1128/IAI.00700-17. Print 2018 Jan.
14. Leelahavanichkul A, Worasilchai N, Wannalardsakun S, Jutivorakool K, Somparn P, Issara-Amphorn J, Tachaboon S, Srisawat N, Finkelman M, Chindamporn A. Gastrointestinal Leakage Detected by Serum (1→3)-β-D-Glucan in Mouse Models and a Pilot Study in Patients with Sepsis. *Shock*. 2016;46:506-518.
15. Kikkert R1, Bulder I, de Groot ER, Aarden LA, Finkelman MA. Potentiation of Toll-like receptor-induced cytokine production by (1→3)-β-D-glucans: implications for the monocyte activation test. *J Endotoxin Res*. 2007;13:140-9.
16. Dennehy KM, Ferwerda G, Faro-Trindade I, Pyz E, Willment JA, Taylor PR, Kerrigan A, Tsoni SV, Gordon S, Meyer-Wentrup F, Adema GJ, Kullberg BJ, Schweighoffer E, Tybulewicz V, Mora-Montes HM, Gow NA, Williams DL, Netea MG, Brown GD. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. *Eur J Immunol*. 2008;38:500-6.
17. Cramer DE, Allendorf DJ, Baran JT, Hansen R, Marroquin J, Li B, Ratajczak J, Ratajczak MZ, Yan J. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. *Blood*. 2006;107:835-40.
18. Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reza R, Wu W, Surma EZ, Laber DA, Ratajczak MZ, Yan J. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. *Stem Cells*. 2008; 26:1231-40.
19. Xia Y, Vetvicka V, Yan J, Hanikýrová M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. *J Immunol*. 1999;162:2281-90.
20. Vetvicka V, Vetvickova J. Glucans and Cancer: Comparison of Commercially Available β-glucans - Part IV. *Anticancer Res*. 2018; 38:1327-1333.
21. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. *J Clin Invest*. 2017 Jun 30;127(7):2829-2841. doi: 10.1172/JCI90562. Epub 2017 May 22.
22. Novakovic B, Habibi E, Wang SY, Arts RJW, Davar R, Megchelenbrink W, Kim B, Kuznetsova T, Kox M, Zwaag J, Matarese F, van Heeringen SJ, Janssen-Megens EM, Sharifi N, Wang C, Keramati F, Schoonenberg V, Flicek P, Clarke L, Pickkers P, Heath S, Gut I, Netea MG, Martens JHA, Logie C, Stunnenberg HG. β-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance. *Cell*. 2016;167:1354-1368.